Publisher Correction: Antibody engineers seek optimal drug targeting TIGIT checkpoint.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32999474.
- Also identified by DOI 10.1038/s41587-020-0714-x.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.